Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
Why 1 Top Analyst Thinks Gilead Sciences Will Soar More Than 25%

RBC Capital Markets analyst Brian Abrahams specifically mentioned a somewhat surprising reason to be excited about Gilead's prospects. He thinks that experimental HIV drug GS-6207 could be a transformative catalyst for Gilead. But GS-6207 is only in phase 1 clinical testing. It could take years for the drug to reach the market.

Published
24 March 2019
From
Motley Fool
Trogarzo’s Effects on Hard-to-Treat HIV Are Stable Over Two Years

Researchers followed a small group of people with highly drug-resistant virus taking Trogarzo (ibalizumab-uiyk) plus an optimized background regimen.

Published
20 March 2019
From
Poz
HIV capsid inhibitor may offer long-term viral suppression

An experimental HIV capsid inhibitor appears safe and may be able to be administered once every three months or less, according to results from an early clinical

Published
11 March 2019
By
Liz Highleyman
Long-acting injectable treatment maintains viral suppression

A combination of two long-acting injectable anti-HIV drugs taken once monthly had a very low rate of treatment failure and a favourable safety profile, according to results

Published
08 March 2019
By
Liz Highleyman
HIV Drug Aiming to Free Patients From Daily Doses Nears Market

A once-a-month shot promising to free patients from daily doses of treatment for HIV, the virus that causes AIDS, is expected to reach the market early next year after hitting goals in a pair of studies.

Published
08 March 2019
From
Bloomberg
Integrase inhibitor treatment leads to greater weight gain

More evidence that HIV integrase inhibitor treatment is associated with weight gain, and that people gain more weight after beginning treatment with an integrase inhibitor than people

Published
07 March 2019
By
Keith Alcorn
Neural tube defects and integrase inhibitors: still waiting for stronger evidence

Researchers are still unable to determine if exposure to integrase inhibitors around conception and in early pregnancy increases the risk of neural tube defects in infants, research

Published
07 March 2019
By
Keith Alcorn
Using anti-cancer immunotherapy to fight HIV

Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have shown that immunotherapy treatments against cancer could reduce the amount of virus that persists in people on triple therapy. In a study published in the journal Nature Communications, they show, in the cells of people living with HIV, how these therapies reveal the virus - until now hidden in the hollows of infected cells - to the immune system.

Published
20 February 2019
From
Eurekalert Medicine & Health
CytoDyn wins key concession from FDA for flagship HIV drug leronlimab trial

The FDA is allowing CytoDyn to increase the dose of the HIV drug leronlimab which patients in its clinical trial are receiving.

Published
04 February 2019
From
Proactive Investors USA & Canada
Two new types of cell therapy could target reservoir cells and permanently stop HIV infection

Two studies published last month described promising new approaches which could stop HIV infecting cells. They could either eliminate or permanently suppress the activity of the so-called

Published
31 January 2019
By
Gus Cairns
← First12345...79Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.